Skip to main content
NBIX logo

Neurocrine Biosciences, Inc.

NBIXNASDAQHealthcareDrug Manufacturers - Specialty & Generic

$135.77Today:- (-)1Y −2.24%

As of Oct 16, 2026 close

Market cap
$14.27B
P/E (TTM)
20.23
Forward P/E
10.04
Dividend yield
-
52-week range
$122.14$186.12
Volume (live)
-
Avg. volume (3M)
1.34M

Neurocrine Biosciences (NBIX) Income Statement

Neurocrine Biosciences reported revenue of $2.86B in fiscal 2025 (fiscal year ended Dec 31, 2025), up 21.4% from $2.36B a year earlier. Net income was $478.60M, up 40.2% year over year, a net margin of 16.7%. Gross margin was 98.2% and operating margin 21.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $959.00M, up 39.5% from the same quarter a year earlier.

Neurocrine Biosciences Income Statement Analysis

Values in billions USD

Scroll to see more
Neurocrine Biosciences, Inc. income statement - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue2.862.361.891.491.131.050.790.450.16
Cost of Revenue0.050.770.040.020.340.010.010.000.00
Gross Profit2.812.321.851.471.121.040.780.450.16
Operating Expenses
Research & Development1.020.740.570.460.430.280.200.160.09
Selling, General & Administrative1.160.990.890.750.580.430.350.250.17
Operating Expenses2.191.751.601.221.020.870.710.410.29
Operating Income0.620.570.250.250.100.160.070.04-0.13
Other Income/Expense
Interest Income0.090.090.000.010.000.000.000.000.00
Interest Expense0.000.130.000.01-0.030.030.030.030.02
Other Income/Expense0.09-0.080.08-0.040.00-0.06-0.03-0.02-0.01
Income
Income Before Tax0.710.490.330.210.100.110.050.02-0.14
Income Tax Expense0.230.140.080.060.01-0.300.010.000.00
Net Income0.480.340.250.150.090.410.040.02-0.14
Net Income - Continuous Operations0.480.340.250.150.090.410.040.02-0.14
Net Income - Discontinued Operations---------
EBITDA0.670.620.420.240.220.150.090.06-0.12
EBIT0.640.600.390.250.21----
Depreciation & Amortization0.030.030.020.020.010.010.010.000.00
Earnings Per Share
Basic EPS5.003.003.002.001.004.00---2.00
Diluted EPS5.003.002.002.001.004.00---2.00
Basic Shares Outstanding0.100.100.100.100.090.090.090.100.09
Diluted Shares Outstanding0.100.100.100.100.100.100.100.100.09

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Neurocrine Biosciences Financial Statements

What was Neurocrine Biosciences's revenue in fiscal 2025?

Neurocrine Biosciences reported revenue of $2.86B in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 21.4% from $2.36B a year earlier.

Is Neurocrine Biosciences profitable?

Yes. Neurocrine Biosciences earned net income of $478.60M in fiscal 2025, a net margin of 16.7%. In fiscal 2024 it earned $341.30M.

What is Neurocrine Biosciences's operating margin?

Neurocrine Biosciences's operating income was $619.10M on revenue of $2.86B in fiscal 2025, an operating margin of 21.6%, compared with 24.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition